Lexicon Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Lexicon Pharmaceuticals
LXRX Stock  USD 0.36  0.02  5.26%   
Lexicon Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Lexicon Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexicon Pharmaceuticals financial statements helps investors assess Lexicon Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexicon Pharmaceuticals' valuation are summarized below:
Gross Profit
-52.9 M
Market Capitalization
138.9 M
Enterprise Value Revenue
0.1244
Revenue
31.1 M
Earnings Share
(0.63)
We have found one hundred twenty available fundamental ratios for Lexicon Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexicon Pharmaceuticals last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 392.3 M in 2025. Enterprise Value is likely to rise to about 356.4 M in 2025

Lexicon Pharmaceuticals Total Revenue

45.68 Million

Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 507.3 K, Interest Expense of 16.4 M or Total Revenue of 45.7 M, as well as many indicators such as Price To Sales Ratio of 7.22, Dividend Yield of 0.0 or PTB Ratio of 1.54. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Lexicon Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets326.8 M298.4 M326.8 M
Pretty Stable
Short and Long Term Debt Total77.9 M108.4 M95.1 M
Pretty Stable
Total Current Liabilities48.4 M45.2 M53.1 M
Very volatile
Property Plant And Equipment Net7 M7.3 M15.9 M
Slightly volatile
Accounts Payable13.4 M14.8 M16.6 M
Very volatile
Cash63.3 M66.7 M171.2 M
Slightly volatile
Non Current Assets Total75 M52.2 M88.4 M
Slightly volatile
Non Currrent Assets Other349.6 K368 K1.6 M
Very volatile
Cash And Short Term Investments208.9 M238 M224.2 M
Pretty Stable
Net Receivables5.1 M3.5 M5.8 M
Very volatile
Common Stock Shares Outstanding336 M320 M131.7 M
Slightly volatile
Short Term Investments139 M171.3 M148.1 M
Very volatile
Non Current Liabilities Total101.3 M107.2 M122.7 M
Very volatile
Other Current Assets6.9 M4.5 M6.2 M
Very volatile
Total Liabilities149.7 M152.5 M175.8 M
Very volatile
Property Plant And Equipment Gross8.9 M9.4 M17.4 M
Slightly volatile
Total Current Assets223.7 M246.2 M236.6 M
Very volatile
Short Term Debt1.1 M1.2 M7.5 M
Slightly volatile
Long Term Debt78.7 M100.3 M92.4 M
Slightly volatile
Common Stock Total Equity212.7 K217.3 K244.2 K
Slightly volatile
Property Plant Equipment1.8 M1.9 M15.2 M
Slightly volatile
Other Liabilities43.1 M26.8 M43.9 M
Pretty Stable
Good Will41.3 M51.2 M43.6 M
Slightly volatile
Intangible Assets41.5 M22.7 M36.9 M
Slightly volatile
Long Term Debt Total282.8 M269.3 M160.2 M
Slightly volatile
Capital Surpluse1.5 B2 B1.4 B
Slightly volatile
Deferred Long Term Liabilities52.6 M34.1 M40.7 M
Very volatile
Non Current Liabilities Other4.6 M4.9 M14.8 M
Slightly volatile
Short and Long Term Debt8.7 M10.5 M13.2 M
Slightly volatile
Net Invested Capital176.5 M246.2 M251.6 M
Slightly volatile
Net Working Capital124.8 M200.9 M172.4 M
Slightly volatile
Capital Stock204.4 K363 K147.1 K
Slightly volatile
Capital Lease Obligations4.8 M8.1 M2.5 M
Slightly volatile

Lexicon Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization507.3 K534 K3.9 M
Very volatile
Total Revenue45.7 M31.1 M51.5 M
Very volatile
Other Operating Expenses149.4 M228.2 M142.1 M
Slightly volatile
Research Development97.2 M84.5 M93.3 M
Very volatile
Total Operating Expenses149.2 M227.6 M141.6 M
Slightly volatile
Selling General Administrative150.3 M143.1 M50.9 M
Slightly volatile
Non Operating Income Net Other1.9 M1.8 M1.6 M
Slightly volatile
Interest Income12.9 M12.3 M5.5 M
Very volatile
Reconciled Depreciation507.3 K534 K2.5 M
Slightly volatile
Extraordinary Items3.2 M3.6 M3.9 M
Slightly volatile

Lexicon Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow21.3 M22.5 M71.9 M
Pretty Stable
Depreciation507.3 K534 K2.2 M
Slightly volatile
Capital Expenditures979.5 K1 M890.5 K
Slightly volatile
End Period Cash Flow69.9 M66.7 M76.1 M
Pretty Stable
Stock Based Compensation9.9 M13.5 M9.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.227.6041396
Pretty Stable
Days Sales Outstanding57.940.785299.7108
Slightly volatile
Stock Based Compensation To Revenue0.410.43439.0595
Slightly volatile
Capex To Depreciation2.031.93071.0412
Slightly volatile
EV To Sales8.58.9471367
Pretty Stable
Inventory Turnover4.382.66676.6162
Slightly volatile
Days Of Inventory On Hand130137444
Slightly volatile
Sales General And Administrative To Revenue327311150
Slightly volatile
Average Inventory0.550.57828.1 K
Very volatile
Research And Ddevelopement To Revenue2.582.718150.2899
Pretty Stable
Capex To Revenue0.03150.03321.054
Pretty Stable
Cash Per Share0.710.74353.4937
Slightly volatile
Intangibles To Total Assets0.150.14930.2198
Pretty Stable
Current Ratio6.975.4415.6731
Pretty Stable
Receivables Turnover8.58.949320.4325
Very volatile
Capex Per Share0.00310.00320.0792
Slightly volatile
Average Receivables2.7 M3.3 M3.6 M
Pretty Stable
Revenue Per Share0.09230.09710.5428
Pretty Stable
Interest Debt Per Share0.370.38741.1172
Slightly volatile
Debt To Assets0.190.36320.2988
Pretty Stable
Operating Cycle160178314
Pretty Stable
Quick Ratio6.965.43595.6621
Pretty Stable
Net Income Per E B T0.540.910.9703
Slightly volatile
Cash Ratio2.551.47314.0021
Slightly volatile
Days Of Inventory Outstanding130137444
Slightly volatile
Days Of Sales Outstanding57.940.785299.7108
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.421.00581.0576
Very volatile
Fixed Asset Turnover5.184.24849.7169
Pretty Stable
Debt Ratio0.190.36320.2988
Pretty Stable
Price Sales Ratio7.227.6041396
Pretty Stable
Asset Turnover0.09890.10420.1361
Very volatile

Lexicon Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap392.3 M212.7 M575.1 M
Slightly volatile
Enterprise Value356.4 M250.3 M519.5 M
Slightly volatile

Lexicon Fundamental Market Drivers

Cash And Short Term Investments238 M

Lexicon Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue32.4 M20 M
Total Revenue31.1 M45.7 M
Cost Of Revenue616 K585.2 K
Stock Based Compensation To Revenue 0.43  0.41 
Sales General And Administrative To Revenue 311.33  326.90 
Research And Ddevelopement To Revenue 2.72  2.58 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.10  0.09 
Ebit Per Revenue(6.34)(6.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY